Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

New application of rabies human immunoglobulin in preparing medicine for preventing and controlling Japanese encephalitis and combined vaccine for rabies and Japanese encephalitis

A technology of immunoglobulin and rabies vaccine, which is applied in the field of biological products, can solve problems such as the difficulty of universal vaccination and poor media control effect, and achieve the effect of scientific immunization procedures, good prevention effect and less vaccination frequency

Inactive Publication Date: 2009-09-09
魏宪义
View PDF0 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In the first quarter of 2006, the Sichuan and other epidemic announcements reported that JE is second only to tuberculosis among the B infectious diseases, and the number of deaths ranks second. The vector control effect is not good, and the JE attenuated live vaccine has a good preventive effect. However, it is difficult to vaccinate the whole population, and there should be effective remedial measures after the onset of JE
But there is no Japanese encephalitis immunoglobulin product for passive immunization to prevent and treat Japanese encephalitis at present in the world

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • New application of rabies human immunoglobulin in preparing medicine for preventing and controlling Japanese encephalitis and combined vaccine for rabies and Japanese encephalitis
  • New application of rabies human immunoglobulin in preparing medicine for preventing and controlling Japanese encephalitis and combined vaccine for rabies and Japanese encephalitis
  • New application of rabies human immunoglobulin in preparing medicine for preventing and controlling Japanese encephalitis and combined vaccine for rabies and Japanese encephalitis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0036] Example 1 Detection of JE antibody content in rabies patient immunoglobulin

[0037] Materials and Methods

[0038] 1. Immunoglobulin

[0039] 1.1 Cytomegalovirus human immunoglobulin: product of Massachusetts Public Health Biologic LaboratoriesUSA, Lot: MIVCMV-198.

[0040] 1.2 Human immunoglobulin for rabies patients: 6 batches, the batch numbers are 200608002, 200605001,

[0041] 200704101, 200704201, 200802602, 200803403; protein content is 96.1, 152.1, 78.3, 77.1, 50.3, 48.6g / L, 2ml / bottle; rabies antibody titer is 128.9, 132, 126, 128.9, 135, 128.9IU / ml. The preparation process is to use purified rabies vaccine for human use (≥2.5IU / branch / person, product of Lanzhou Institute of Biological Products of the Ministry of Health or Shenyang Andy Biopharmaceutical Co., Ltd.), and the vaccine immunization procedure is carried out according to the instruction manual of purified rabies vaccine for human use. The plasma donors were given basic immunizations on days 0, ...

Embodiment 2

[0070] Comparison of Japanese Encephalitis Antibody in Embodiment 2 Rabies Immunoglobulin and Other Immunoglobulins

[0071] 1. Comparison of JE antibody titers and rabies antibody titers of various immunoglobulin test products

[0072] In order to investigate whether there is a reciprocal cross-antigen between JE and rabies virus, the JE and rabies antibody titers of the test products were compared. Compared with negative common serum, the rabies antibody titer of JE positive serum did not increase significantly. Therefore, the JE antibody titer in the immunoglobulin of rabies patients should not be caused by JE vaccine immunization (or latent infection). There is no relationship between JE antibody titer and rabies antibody titer found in other tested products.

[0073] 2. Comparison of rabies antibody titer and JE antibody titer of different batches of rabies patient immunoglobulin

[0074] In order to verify that there is a unidirectional cross-antigen between rabies an...

Embodiment 3

[0081] Example 3 Determination of Dosage of Preventing and Treating Japanese Encephalitis and Rabies Using Rabies Immunoglobulin

[0082] When using rabies patient immunoglobulin to prevent and treat Japanese encephalitis, the dosage and usage of the drug are calculated according to the titer of rabies antibody: the specification of rabies patient immunoglobulin is 100IU / ml (the potency of JE antibody is about 400±100U / ml ), 5-10IU / kg is used for emergency passive immunization prevention, and the total amount of medicine for a person with a body weight of 50kg is 250-500IU (including JE potency is about 1000-2000U). The titer will reach the level of 250-500U / L (calculated according to 4L serum / 50kg), and the half-life of IgG terminal elimination is 24.2 days, so a single dose should be used for emergency passive immunization prevention; for passive immunization therapy, it should be used in the early stage of the disease , taking into account the tolerance of intramuscular inj...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the field of biological products, in particular to a new application of the existing product-rabies human immunoglobulin. The technical proposal of the invention is the new application of rabies human immunoglobulin in preparing medicine for preventing and controlling Japanese encephalitis. The invention also provides a combined vaccine for rabies and Japanese encephalitis. The vaccine of the invention has better effect than conventional Japanese encephalitis vaccine in preventing and controlling Japanese encephalitis and fundamental immunity for resisting the rabies virus is obtained. The combined vaccine features scientific immunization schedule, few times of vaccine inoculation, easy promotion of inoculation and good effect in boostering immunization in case of emergency in preventing and controlling the rabies. The antibody and the vaccine jointly solve the technical and application problems of preventing and controlling the Japanese encephalitis and the rabies, thus enjoying great social and economic significance.

Description

technical field [0001] The invention belongs to the field of biological products, and specifically relates to the use of the existing product rabies patient immunoglobulin in the preparation of medicines for preventing and treating Japanese encephalitis and a combined vaccine of rabies and Japanese encephalitis. Background technique [0002] Rabies virus (Rabies virus) is a single-stranded negative-sense RNA virus belonging to the Rhabdoviridae family (Rhabdoviridae) and the genus Lassavirus (Lyssavirus). The incidence rate of humans after being bitten by sick dogs is 15-30%, and the incubation period is generally 1-3 months Months later, no viremia was produced, and the main clinical symptom was progressive encephalitis. [0003] According to reports, the incubation period of 74 rabies patients ranged from 22 to 118 days, with a mean of 52.5 days. Among them, the 5-15 age group averaged 38.5 days. A 2-year-old child developed symptoms 13 days after a dog bite. After 45 d...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K39/395A61K39/205A61K39/295A61K39/12A61P31/14
CPCY02A50/30
Inventor 魏宪义
Owner 魏宪义
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com